Rani Therapeutics Holdings, Inc.
RANI- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001856725
In the last 90 days, Rani Therapeutics Holdings, Inc. insiders filed 2 open-market purchases and 2 sales; 68 institutions reported holding it in 13F filings for Q2 2026, worth $34.7M in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding Rani Therapeutics Holdings, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Of which not filed for Q2 2023 | Q2 2023 | Change |
|---|---|---|---|---|
| Holders | 36 | 1 | 35 | 0 |
| Shares | 3.00M | 48.1K | 3.23M | +276.0K (+9.4%) |
| Value | $15.5M | $248.0K | $13.3M | −$1.97M (−12.9%) |
1 institution that held it in Q1 2023 haven't filed for Q2 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (4)
Institutions that held Rani Therapeutics Holdings, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| King Luther Capital Management Corp | 56,129 | $231.3K | 0.00% |
| Prime Capital Investment Advisors, LLC | 16,682 | $68.7K | 0.00% |
| IAG Wealth Partners, LLC | 1,005 | $4.14K | 0.00% |
| Rhumbline Advisers | 312 | $1.28K | 0.00% |
Sold out (4)
Institutions that held Rani Therapeutics Holdings, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Susquehanna International Group, LLP | 70,772 | $365.2K |
| Goldman Sachs Group Inc | 33,532 | $173.0K |
| Qube Research & Technologies Ltd | 19,907 | $102.7K |
| Icon Wealth Partners, LLC | 12,757 | $65.8K |
Not filed for Q2 2023 yet (1)
Institutions that held Rani Therapeutics Holdings, Inc. at the end of Q1 2023 and haven't filed a 13F for Q2 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Aspireon Wealth Advisors | 48,129 | $248.0K |